Supernus Pharmaceuticals Swings to Q2 Net Loss, Revenue Rises; Fiscal 2026 Revenue Outlook Raised

MT Newswires Live08-03

Supernus Pharmaceuticals, Inc. (SUPN) reported a Q2 net loss Monday of $1.01 per share, swinging from earnings of $0.40 a year earlier.

Three analysts surveyed by FactSet expected earnings of $0.04 per share.

Revenue for the quarter ended June 30 was $219.1 million, up from $165.5 million a year earlier.

Analysts expected $205.3 million.

Supernus now expects fiscal 2026 revenue of about $860 million to $890 million, compared with its previous outlook of $840 million to $870 million. Analysts expect $867.3 million.

The company had about $372.1 million in cash, cash equivalents, and current marketable securities as of June 30.

Shares of the company were up 27% in Monday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2656837375?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-03 19:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2656837375","market":"hk","top_or_hot":-1,"title":"Supernus Pharmaceuticals Swings to Q2 Net Loss, Revenue Rises; Fiscal 2026 Revenue Outlook Raised","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SUPN\">Supernus Pharmaceuticals</a>, Inc. (SUPN) reported a Q2 net loss Monday of $1.01 per share, swinging from earnings of $0.40 a year earlier.</p><p>Three analysts surveyed by FactSet expected earnings of $0.04 per share.</p><p>Revenue for the quarter ended June 30 was $219.1 million, up from $165.5 million a year earlier.</p><p>Analysts expected $205.3 million.</p><p>Supernus now expects fiscal 2026 revenue of about $860 million to $890 million, compared with its previous outlook of $840 million to $870 million. Analysts expect $867.3 million.</p><p>The company had about $372.1 million in cash, cash equivalents, and current marketable securities as of June 30.</p><p>Shares of the company were up 27% in Monday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Supernus Pharmaceuticals Swings to Q2 Net Loss, Revenue Rises; Fiscal 2026 Revenue Outlook Raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSupernus Pharmaceuticals Swings to Q2 Net Loss, Revenue Rises; Fiscal 2026 Revenue Outlook Raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-03 19:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/SUPN\">Supernus Pharmaceuticals</a>, Inc. (SUPN) reported a Q2 net loss Monday of $1.01 per share, swinging from earnings of $0.40 a year earlier.</p><p>Three analysts surveyed by FactSet expected earnings of $0.04 per share.</p><p>Revenue for the quarter ended June 30 was $219.1 million, up from $165.5 million a year earlier.</p><p>Analysts expected $205.3 million.</p><p>Supernus now expects fiscal 2026 revenue of about $860 million to $890 million, compared with its previous outlook of $840 million to $870 million. Analysts expect $867.3 million.</p><p>The company had about $372.1 million in cash, cash equivalents, and current marketable securities as of June 30.</p><p>Shares of the company were up 27% in Monday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SUPN","symbol_name":"Supernus Pharmaceuticals","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2656837375","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2656837375","pubTimestamp":1785755492,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Supernus Pharmaceuticals, Inc.  reported a Q2 net loss Monday of $1.01 per share, swinging from earnings of $0.40 a year earlier.Three analysts surveyed by FactSet expected earnings of $0.04 per share.Revenue for the quarter ended June 30 was $219.1 million, up from $165.5 million a year earlier.Analysts expected $205.3 million.Supernus now expects fiscal 2026 revenue of about $860 million to $890 million, compared with its previous outlook of $840 million to $870 million. Analysts expect $867.3 million.The company had about $372.1 million in cash, cash equivalents, and current marketable securities as of June 30.Shares of the company were up 27% in Monday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SUPN":"Supernus Pharmaceuticals"},"translate_title":"Supernus Pharmaceuticals 第二季度净亏损，收入增长；2026 财年收入展望上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SUPN":1.5},"content_text":"Supernus Pharmaceuticals, Inc. (SUPN) reported a Q2 net loss Monday of $1.01 per share, swinging from earnings of $0.40 a year earlier.Three analysts surveyed by FactSet expected earnings of $0.04 per share.Revenue for the quarter ended June 30 was $219.1 million, up from $165.5 million a year earlier.Analysts expected $205.3 million.Supernus now expects fiscal 2026 revenue of about $860 million to $890 million, compared with its previous outlook of $840 million to $870 million. Analysts expect $867.3 million.The company had about $372.1 million in cash, cash equivalents, and current marketable securities as of June 30.Shares of the company were up 27% in Monday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2656837375","isCrawlerRequest":true}